BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
May 24, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S....
Ollie’s Bargain Outlet Winning Bidder in Bankruptcy Auction to Acquire Eleven Former 99 Cents Only Stores
May 24, 2024 07:30 ET
|
Ollie's Bargain Outlet Holdings, Inc.
HARRISBURG, Pa., May 24, 2024 (GLOBE NEWSWIRE) -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today announced that at the conclusion of a final sale hearing, the United...
Syntec Optics Holdings, Inc. (Nasdaq: OPTX) Reports Fourth Quarter 2023, Full Year 2023 and First Quarter 2024 Financial Results
May 24, 2024 07:26 ET
|
Syntec Optics
ROCHESTER, NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (“Syntec Optics” or the “Company”) (Nasdaq: OPTX), a leading provider of mission-critical optics to scientific and...
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
May 23, 2024 21:03 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 23, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from...
LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results
May 23, 2024 19:00 ET
|
LexinFintech Holdings Ltd.
SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China,...
Huize Holding Limited Reports First Quarter 2024 Unaudited Financial Results
May 23, 2024 18:00 ET
|
Huize Holding Limited
SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024 18:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies...
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:51 ET
|
Coherus BioSciences, Inc.
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...